Schneider Capital Management Corp Has $1.52 Million Position in Insys Therapeutics Inc (INSY)
Schneider Capital Management Corp increased its holdings in Insys Therapeutics Inc (NASDAQ:INSY) by 100.0% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 119,973 shares of the specialty pharmaceutical company’s stock after buying an additional 60,000 shares during the period. Schneider Capital Management Corp owned 0.17% of Insys Therapeutics worth $1,518,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. KCG Holdings Inc. boosted its holdings in Insys Therapeutics by 42.0% in the 1st quarter. KCG Holdings Inc. now owns 26,160 shares of the specialty pharmaceutical company’s stock worth $275,000 after buying an additional 7,735 shares during the period. Weiss Multi Strategy Advisers LLC boosted its holdings in Insys Therapeutics by 114.3% in the 1st quarter. Weiss Multi Strategy Advisers LLC now owns 45,000 shares of the specialty pharmaceutical company’s stock valued at $473,000 after purchasing an additional 24,000 shares during the period. JPMorgan Chase & Co. boosted its holdings in Insys Therapeutics by 37.9% in the 1st quarter. JPMorgan Chase & Co. now owns 45,694 shares of the specialty pharmaceutical company’s stock valued at $480,000 after purchasing an additional 12,561 shares during the period. Tudor Investment Corp ET AL boosted its holdings in Insys Therapeutics by 16.9% in the 1st quarter. Tudor Investment Corp ET AL now owns 49,589 shares of the specialty pharmaceutical company’s stock valued at $521,000 after purchasing an additional 7,184 shares during the period. Finally, Marshall Wace North America L.P. bought a new position in Insys Therapeutics in the 2nd quarter valued at $612,000. 25.44% of the stock is owned by institutional investors.
In related news, CEO Saeed Motahari bought 5,500 shares of the company’s stock in a transaction that occurred on Thursday, August 10th. The stock was purchased at an average price of $8.92 per share, for a total transaction of $49,060.00. Following the completion of the transaction, the chief executive officer now owns 15,400 shares in the company, valued at $137,368. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder John N. Kapoor Trust Dated Sept bought 17,500 shares of the company’s stock in a transaction that occurred on Friday, August 11th. The shares were bought at an average price of $8.93 per share, with a total value of $156,275.00. Following the transaction, the insider now owns 31,982 shares of the company’s stock, valued at approximately $285,599.26. The disclosure for this purchase can be found here. 67.90% of the stock is currently owned by corporate insiders.
Shares of Insys Therapeutics Inc (NASDAQ INSY) traded down 3.640% on Friday, reaching $7.545. 371,984 shares of the company’s stock traded hands. The firm’s 50-day moving average is $9.11 and its 200-day moving average is $10.93. Insys Therapeutics Inc has a 52-week low of $7.53 and a 52-week high of $15.06. The stock’s market cap is $548.49 million.
Insys Therapeutics (NASDAQ:INSY) last issued its earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported $0.03 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.09) by $0.12. Insys Therapeutics had a negative net margin of 19.22% and a negative return on equity of 12.29%. The firm had revenue of $42.60 million during the quarter, compared to analyst estimates of $36.90 million. During the same quarter in the prior year, the business earned $0.13 earnings per share. Insys Therapeutics’s revenue for the quarter was down 38.4% on a year-over-year basis. Analysts anticipate that Insys Therapeutics Inc will post ($0.33) EPS for the current fiscal year.
INSY has been the subject of several analyst reports. Oppenheimer Holdings, Inc. reissued a “hold” rating on shares of Insys Therapeutics in a report on Tuesday, July 4th. BidaskClub raised shares of Insys Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, July 8th. Zacks Investment Research raised shares of Insys Therapeutics from a “sell” rating to a “strong-buy” rating and set a $15.00 price target for the company in a report on Wednesday, July 12th. Piper Jaffray Companies set a $10.00 price target on shares of Insys Therapeutics and gave the company a “hold” rating in a report on Wednesday, July 26th. Finally, Royal Bank Of Canada cut their price target on shares of Insys Therapeutics from $16.00 to $14.00 and set an “outperform” rating for the company in a report on Friday, August 4th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $13.25.
Insys Therapeutics Company Profile
Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.
Want to see what other hedge funds are holding INSY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insys Therapeutics Inc (NASDAQ:INSY).
Receive News & Stock Ratings for Insys Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics Inc and related stocks with our FREE daily email newsletter.